Top News

Ligand Buys IP From AstraZeneca




San Diego-based biopharmaceuticals firm Ligand Pharmaceuticals said today that it has purchased certain intellectual property and royalties from AstraZeneca's subsidiary, MedImmune. According to Ligand, it paid $2.75M for the IP and interest in future milestones and royalties for MEDI-528, an IL-9 antibody program being developed by MedImmune. The compound has possible applications in treating asthma.


 

Marketplace


 

 

Latest Headlines

Browse Issues

 
 

Keep up with all of the latest Southern California high tech news via email (it's free!)



or Cancel